Foghorn Therapeutics/$FHTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Foghorn Therapeutics
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
Ticker
$FHTX
Sector
Primary listing
Employees
106
Headquarters
Website
FHTX Metrics
BasicAdvanced
$245m
-
-$1.17
2.97
-
Price and volume
Market cap
$245m
Beta
2.97
52-week high
$6.95
52-week low
$3.27
Average daily volume
168k
Financial strength
Current ratio
2.92
Quick ratio
2.851
Long term debt to equity
-52.522
Total debt to equity
-54.96
Profitability
EBITDA (TTM)
-78.024
Gross margin (TTM)
-190.88%
Net profit margin (TTM)
-266.88%
Operating margin (TTM)
-286.16%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-21.00%
Return on equity (TTM)
109.12%
Valuation
Price to revenue (TTM)
9.575
Price to book
-3.21
Price to tangible book (TTM)
-3.21
Price to free cash flow (TTM)
-3.091
Free cash flow yield (TTM)
-32.35%
Free cash flow per share (TTM)
-1.352
Growth
Revenue change (TTM)
20.08%
Earnings per share change (TTM)
-13.09%
3-year revenue growth (CAGR)
11.04%
3-year earnings per share growth (CAGR)
-24.40%
What the Analysts think about FHTX
Analyst ratings (Buy, Hold, Sell) for Foghorn Therapeutics stock.
FHTX Financial Performance
Revenues and expenses
FHTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs